Heartware International (HTWR) 95.42 $HTWR
Insider Trading Alert - MU, O And HTWR Traded By Insiders
at The Street - Mon May 12, 10:15AM CDT
Stocks with insider trader activity include MU, O and HTWR
HeartWare Presentation At The Bank Of America Merrill Lynch 2014 Health Care Conference To Be Webcast
PR Newswire - Fri May 09, 8:15AM CDT
HeartWare International, Inc. (NASDAQ:HTWR), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that CEO Doug Godshall is scheduled to present at the Bank of America Merrill Lynch 2014 Health Care Conference at 12:00 p.m. PDT (3:00 p.m. EDT) on Tuesday, May 13, 2014. The conference is being held May 12-15 at the Encore at Wynn in Las Vegas.
Nasdaq stocks posting largest percentage increases
AP - Thu May 01, 5:07PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
Heartware International Breaks Above 200-Day Moving Average - Bullish for HTWR
MarketNewsVideo.com - Thu May 01, 10:44AM CDT
In trading on Thursday, shares of Heartware International Inc crossed above their 200 day moving average of $88.31, changing hands as high as $95.19 per share. Heartware International Inc shares are currently trading up about 9.9% on the day.
HeartWare International Reports $66.5 Million In First Quarter 2014 Revenue; 35% Increase From First Quarter 2013
PR Newswire - Thu May 01, 5:59AM CDT
HeartWare International, Inc. (NASDAQ: HTWR), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced revenue of $66.5 million for the first quarter ended March 31, 2014, a 35% increase compared to $49.2 million in revenue for the same period of 2013.
HeartWare International Issues Voluntary Device Correction For HeartWare® Batteries
PR Newswire - Thu May 01, 5:50AM CDT
HeartWare International, Inc. (Nasdaq: HTWR), today issued a voluntary Urgent Medical Device Correction related to all HeartWare® Ventricular Assist System batteries, product codes 1650 and 1650-DE. In letters to clinicians and patients, the company reports an observed increase in complaints related to earlier-than-expected battery depletion and routine battery handling.
HeartWare Issues Reminder To December 2013 Driveline Connector Device Correction
PR Newswire - Thu Apr 24, 4:50PM CDT
HeartWare International, Inc. (Nasdaq: HTWR) today announced issuance of a clinician and patient reminder concerning the Urgent Medical Device Correction distributed to all of its clinical sites by the company in December 2013. The device correction discussed eight complaints that the locking mechanism of the driveline connector of the HeartWare® Ventricular Assist System had failed to engage and instructed clinicians to inspect patient driveline connectors. To ensure full awareness, the company is in the process of redistributing this information to clinicians and patients.
HeartWare Schedules First Quarter Conference Call And Webcast
PR Newswire - Tue Apr 22, 4:30PM CDT
HeartWare International, Inc. (NASDAQ:HTWR) has scheduled a conference call to discuss its financial results for the three months ended March 31, 2014, at 8:00 a.m. U.S. Eastern Daylight Time on Thursday, May 1, 2014. The Company plans to release the financial results prior to the conference call.
Upgrade Alert for HeartWare International (HTWR)
Comtex SmarTrend(R) - Tue Apr 15, 6:59AM CDT
HeartWare International (NASDAQ:HTWR) was upgraded from Perform to Outperform at Oppenheimer today. The stock closed yesterday at $86.57 on volume of 410,000 shares, above average daily volume of 215,000. HeartWare International has overhead space with shares priced $86.57, or 18.0% below the average consensus analyst price target of $105.64. The stock should find initial resistance at its 200-day moving average (MA) of $88.89 and further resistance at its 50-day MA of $94.10.
HeartWare International Rises 6.53% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Mon Apr 14, 5:52PM CDT
HeartWare International (NASDAQ:HTWR) traded in a range yesterday that spanned from a low of $81.38 to a high of $86.86. Yesterday, the shares gained 6.5%, which took the trading range above the 3-day high of $85.84 on volume of 410,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Improvement in Cardiac Function with Particulate ECM alone and adjunct to LVAD Demonstrated in Bovine Model
Business Wire - Mon Apr 14, 8:31AM CDT
New research presented Sunday at the 34th Annual meeting of the International Society for Heart and Lung Transplantation (ISHLT) demonstrated the CorMatrix particulate extracellular matrix (P-ECM) alone and as an adjunct to HeartWare International Inc.'s left ventricular assist device (LVAD) improved cardiac function in a bovine ischemic heart failure model, as compared to LVAD alone. Mark S. Slaughter, M.D., of the Department of Cardiovascular and Thoracic Surgery and his research team from the University of Louisville, Louisville, KY, presented data during the ISHLT Mechanical Circulatory Support: Bench to Bedside Session in his presentation entitled "Myocardial Regeneration and Recovery with Extracellular Matrix and LVAD Support" on Sunday Morning.
Downtrend Call Working As HeartWare International Stock Falls 12.7% (HTWR)
Comtex SmarTrend(R) - Fri Apr 11, 11:18AM CDT
SmarTrend identified a Downtrend for HeartWare International (NASDAQ:HTWR) on March 7th, 2014 at $92.57. In approximately 1 month, HeartWare International has returned 12.73% as of today's recent price of $80.79.
Heartware International Down to Sell - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 18, 2:20PM CDT
Heartware continues to make losses due to higher costs and expenses.
HeartWare Presentation At The 2014 Barclays Global Healthcare Conference To Be Webcast
PR Newswire - Fri Mar 07, 8:00AM CST
HeartWare International, Inc. (NASDAQ:HTWR), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that CEO Doug Godshall is scheduled to present at the 2014 Barclays Global Healthcare Conference at 10:15 a.m. EDT on Tuesday, March 11, 2014. The conference is being held March 11-13 at Loews Miami Hotel.
Thoratec Warns About HeartMate Controller - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 06, 2:00PM CST
Investors reacted negatively to the news, resulting in a 2.7% fall in THOR shares to $36.22 after the market closed yesterday
HeartWare Sees Narrower Loss but Misses Ests - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 03, 8:55AM CST
For full year 2013, HeartWare's loss was also narrower at $52.0 million or $3.24 per share compared with $86.6 million or $6.07 per share in 2012.
HeartWare International Reports Fourth Quarter 2013 Results
PR Newswire - Thu Feb 27, 6:00AM CST
HeartWare International, Inc. (NASDAQ: HTWR), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced revenue of $53.1 million for the fourth quarter ended December 31, 2013, a 62% increase compared to $32.7 million in revenue for the same period of 2012. For the fiscal year 2013, the company generated revenue of $207.9 million, an 87% increase compared to revenue of $110.9 million in fiscal year 2012.
HeartWare Presentation At The Raymond James 35th Annual Institutional Investors Conference To Be Webcast
PR Newswire - Wed Feb 26, 3:00PM CST
HeartWare International, Inc. (NASDAQ: HTWR), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that CEO Doug Godshall is scheduled to present at the Raymond James 35th Annual Institutional Investors Conference at 4:35 p.m. EST on Tuesday, March 4, 2014. The conference is being held March 2-5 at JW Marriott Grande Lakes, Orlando, Florida.
Insider Trading Alert - MU, O And HTWR Traded By Insiders
at The Street - Mon May 12, 10:15AM CDT
Stocks with insider trader activity include MU, O and HTWR
HeartWare Presentation At The Bank Of America Merrill Lynch 2014 Health Care Conference To Be Webcast
PR Newswire - Fri May 09, 8:15AM CDT
HeartWare International, Inc. (NASDAQ:HTWR), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that CEO Doug Godshall is scheduled to present at the Bank of America Merrill Lynch 2014 Health Care Conference at 12:00 p.m. PDT (3:00 p.m. EDT) on Tuesday, May 13, 2014. The conference is being held May 12-15 at the Encore at Wynn in Las Vegas.
Nasdaq stocks posting largest percentage increases
AP - Thu May 01, 5:07PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
Heartware International Breaks Above 200-Day Moving Average - Bullish for HTWR
MarketNewsVideo.com - Thu May 01, 10:44AM CDT
In trading on Thursday, shares of Heartware International Inc crossed above their 200 day moving average of $88.31, changing hands as high as $95.19 per share. Heartware International Inc shares are currently trading up about 9.9% on the day.
HeartWare International Reports $66.5 Million In First Quarter 2014 Revenue; 35% Increase From First Quarter 2013
PR Newswire - Thu May 01, 5:59AM CDT
HeartWare International, Inc. (NASDAQ: HTWR), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced revenue of $66.5 million for the first quarter ended March 31, 2014, a 35% increase compared to $49.2 million in revenue for the same period of 2013.
HeartWare International Issues Voluntary Device Correction For HeartWare® Batteries
PR Newswire - Thu May 01, 5:50AM CDT
HeartWare International, Inc. (Nasdaq: HTWR), today issued a voluntary Urgent Medical Device Correction related to all HeartWare® Ventricular Assist System batteries, product codes 1650 and 1650-DE. In letters to clinicians and patients, the company reports an observed increase in complaints related to earlier-than-expected battery depletion and routine battery handling.
HeartWare Issues Reminder To December 2013 Driveline Connector Device Correction
PR Newswire - Thu Apr 24, 4:50PM CDT
HeartWare International, Inc. (Nasdaq: HTWR) today announced issuance of a clinician and patient reminder concerning the Urgent Medical Device Correction distributed to all of its clinical sites by the company in December 2013. The device correction discussed eight complaints that the locking mechanism of the driveline connector of the HeartWare® Ventricular Assist System had failed to engage and instructed clinicians to inspect patient driveline connectors. To ensure full awareness, the company is in the process of redistributing this information to clinicians and patients.
HeartWare Schedules First Quarter Conference Call And Webcast
PR Newswire - Tue Apr 22, 4:30PM CDT
HeartWare International, Inc. (NASDAQ:HTWR) has scheduled a conference call to discuss its financial results for the three months ended March 31, 2014, at 8:00 a.m. U.S. Eastern Daylight Time on Thursday, May 1, 2014. The Company plans to release the financial results prior to the conference call.
Upgrade Alert for HeartWare International (HTWR)
Comtex SmarTrend(R) - Tue Apr 15, 6:59AM CDT
HeartWare International (NASDAQ:HTWR) was upgraded from Perform to Outperform at Oppenheimer today. The stock closed yesterday at $86.57 on volume of 410,000 shares, above average daily volume of 215,000. HeartWare International has overhead space with shares priced $86.57, or 18.0% below the average consensus analyst price target of $105.64. The stock should find initial resistance at its 200-day moving average (MA) of $88.89 and further resistance at its 50-day MA of $94.10.
HeartWare International Rises 6.53% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Mon Apr 14, 5:52PM CDT
HeartWare International (NASDAQ:HTWR) traded in a range yesterday that spanned from a low of $81.38 to a high of $86.86. Yesterday, the shares gained 6.5%, which took the trading range above the 3-day high of $85.84 on volume of 410,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Improvement in Cardiac Function with Particulate ECM alone and adjunct to LVAD Demonstrated in Bovine Model
Business Wire - Mon Apr 14, 8:31AM CDT
New research presented Sunday at the 34th Annual meeting of the International Society for Heart and Lung Transplantation (ISHLT) demonstrated the CorMatrix particulate extracellular matrix (P-ECM) alone and as an adjunct to HeartWare International Inc.'s left ventricular assist device (LVAD) improved cardiac function in a bovine ischemic heart failure model, as compared to LVAD alone. Mark S. Slaughter, M.D., of the Department of Cardiovascular and Thoracic Surgery and his research team from the University of Louisville, Louisville, KY, presented data during the ISHLT Mechanical Circulatory Support: Bench to Bedside Session in his presentation entitled "Myocardial Regeneration and Recovery with Extracellular Matrix and LVAD Support" on Sunday Morning.
Downtrend Call Working As HeartWare International Stock Falls 12.7% (HTWR)
Comtex SmarTrend(R) - Fri Apr 11, 11:18AM CDT
SmarTrend identified a Downtrend for HeartWare International (NASDAQ:HTWR) on March 7th, 2014 at $92.57. In approximately 1 month, HeartWare International has returned 12.73% as of today's recent price of $80.79.
Heartware International Down to Sell - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 18, 2:20PM CDT
Heartware continues to make losses due to higher costs and expenses.
HeartWare Presentation At The 2014 Barclays Global Healthcare Conference To Be Webcast
PR Newswire - Fri Mar 07, 8:00AM CST
HeartWare International, Inc. (NASDAQ:HTWR), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that CEO Doug Godshall is scheduled to present at the 2014 Barclays Global Healthcare Conference at 10:15 a.m. EDT on Tuesday, March 11, 2014. The conference is being held March 11-13 at Loews Miami Hotel.
Thoratec Warns About HeartMate Controller - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 06, 2:00PM CST
Investors reacted negatively to the news, resulting in a 2.7% fall in THOR shares to $36.22 after the market closed yesterday
HeartWare Sees Narrower Loss but Misses Ests - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 03, 8:55AM CST
For full year 2013, HeartWare's loss was also narrower at $52.0 million or $3.24 per share compared with $86.6 million or $6.07 per share in 2012.
HeartWare International Reports Fourth Quarter 2013 Results
PR Newswire - Thu Feb 27, 6:00AM CST
HeartWare International, Inc. (NASDAQ: HTWR), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced revenue of $53.1 million for the fourth quarter ended December 31, 2013, a 62% increase compared to $32.7 million in revenue for the same period of 2012. For the fiscal year 2013, the company generated revenue of $207.9 million, an 87% increase compared to revenue of $110.9 million in fiscal year 2012.
HeartWare Presentation At The Raymond James 35th Annual Institutional Investors Conference To Be Webcast
PR Newswire - Wed Feb 26, 3:00PM CST
HeartWare International, Inc. (NASDAQ: HTWR), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that CEO Doug Godshall is scheduled to present at the Raymond James 35th Annual Institutional Investors Conference at 4:35 p.m. EST on Tuesday, March 4, 2014. The conference is being held March 2-5 at JW Marriott Grande Lakes, Orlando, Florida.
